These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Aminopeptidase inhibitor ubenimex (bestatin) inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity.
    Author: Inoi K, Goto S, Nomura S, Isobe K, Nawa A, Okamoto T, Tomoda Y.
    Journal: Anticancer Res; 1995; 15(5B):2081-7. PubMed ID: 8572606.
    Abstract:
    Ubenimex (bestatin), a potent inhibitor of aminopeptidases, is known to have immunomodulatory and host-mediated antitumor activities. In this paper, we investigated the inhibitory effects of bestatin on the growth of human choriocarcinoma both in vitro and in vivo using the established choriocarcinoma cell line NaUCC-4. Bestatin inhibited the in vitro proliferation of NaUCC-4 cells concentration- and time-dependently at more than 72 h incubation. DNA histograms by flow cytometric analysis revealed that exposure to bestatin at 5 to 20 micrograms/ml for 72 h caused mild accumulation of NaUCC-4 cells in the G0/G1 phase of the cell cycle, although no clear arrest was observed in any phase of cell cycle. In vivo antitumor activity of bestatin was examined using the NaUCC-4 choriocarcinoma-xenografted nude mouse model. Tumor growth was significantly inhibited by daily i.p. administration of bestatin for 4 weeks at doses of 2 and 20 mg/kg (p < 0.01 and p < 0.001, respectively), but not by 0.2 mg/kg as compared with control. No significant augmentation of NK activity or B cell mitogenicity in spleen cells taken from these NaUCC-4-hearing nude mice was observed following treatment with bestatin at either 2 or 20 mg/kg. These results indicate that bestatin inhibits the growth of NaUCC-4 choriocarcinoma in vivo as well as in vitro not via potentiation of effector cells but rather by its direct cytostatic activity, and suggest that bestatin may have an additional therapeutic property besides as a BRM for its use in the treatment of choriocarcinoma.
    [Abstract] [Full Text] [Related] [New Search]